Select a medication above to begin.
Black Box Warnings .
Cardiovascular and Other Risks
estrogens +/- progestins not indicated for cardiovascular dz or dementia prevention; incr. risk of stroke and DVT (from WHI estrogen-alone substudy) and MI, stroke, PE/DVT, and invasive breast CA (from WHI estrogen/progestin substudy) in postmenopausal women; incr. risk of probable dementia in postmenopausal women 65 yo and older on a WHI regimen x4-5y; WHI regimens = conj. estrogens 0.625 mg/day w/ or w/o medroxyprogesterone 2.5 mg/day, other doses or estrogen/progestin combos not studied, but assume similar risk; use lowest effective estrogen dose, shortest duration based on individual tx goals and risks
Endometrial Cancer Risk
unopposed estrogen use incr. risk if intact uterus; adding progestin may decr. risk of endometrial hyperplasia (possible precursor to endometrial CA); use adequate diagnostic measures such as endometrial sampling to rule out malignancy if undiagnosed persistent or recurrent abnormal genital bleeding
Adult Dosing .
Dosage forms: TAB: 0.3 mg/1.5 mg, 0.45 mg/1.5 mg, 0.625 mg/2.5 mg, 0.625 mg/5 mg
vasomotor sx, mod-severe menopausal
- [1 tab PO qd]
- Start: 0.3 mg/1.5 mg PO qd; Info: use lowest effective estrogen dose, shortest effective tx duration
vulvovaginal atrophy, menopausal
- [1 tab PO qd]
- Start: 0.3 mg/1.5 mg PO qd; Info: use lowest effective estrogen dose, shortest effective tx duration; not preferred if local sx only
osteoporosis prevention, postmenopausal
- [1 tab PO qd]
- Start: 0.3 mg/1.5 mg PO qd; Info: weigh estrogen tx risk/benefit; fixed-dose regimen may not contain lowest effective estrogen dose
renal dosing
- [see below]
- renal dz: not defined, caution advised
- HD/PD: not defined, caution advised
hepatic dosing
- [see below]
- hepatic impairment: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.